BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16141208)

  • 1. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
    Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
    J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
    Andersen LM; Wind T; Hansen HD; Andreasen PA
    Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
    Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
    Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
    Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
    Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.
    Roodbeen R; Paaske B; Jiang L; Jensen JK; Christensen A; Nielsen JT; Huang M; Mulder FA; Nielsen NC; Andreasen PA; Jensen KJ
    Chembiochem; 2013 Nov; 14(16):2179-88. PubMed ID: 24115455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding mechanism of a peptidic cyclic serine protease inhibitor.
    Jiang L; Svane AS; Sørensen HP; Jensen JK; Hosseini M; Chen Z; Weydert C; Nielsen JT; Christensen A; Yuan C; Jensen KJ; Nielsen NC; Malmendal A; Huang M; Andreasen PA
    J Mol Biol; 2011 Sep; 412(2):235-50. PubMed ID: 21802428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
    Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
    J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
    Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
    Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
    Li Y; Lawrence DA; Zhang L
    J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R; Petersen TE; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a high affinity inhibitor of urokinase-type plasminogen activator by phage display of ecotin.
    Wang CI; Yang Q; Craik CS
    J Biol Chem; 1995 May; 270(20):12250-6. PubMed ID: 7744876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition.
    Ibarra CA; Blouse GE; Christian TD; Shore JD
    J Biol Chem; 2004 Jan; 279(5):3643-50. PubMed ID: 14594804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
    Xu P; Andreasen PA; Huang M
    Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.